指南与共识泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

子宫内膜癌的放射治疗:美国放射肿瘤学会临床实践指南

Radiation Therapy for Endometrial Cancer: An American Society for Radiation Oncology Clinical Practice Guideline.
指南 / 共识 · Pract Radiat Oncol · 2022-10-22

美国放射肿瘤学会组建多学科工作组,基于系统文献综述和预设共识方法,针对子宫内膜癌辅助治疗6个关键问题制定推荐。推荐根据临床病理风险因素给予阴道近距离放疗或外照射放疗以降低阴道和/或盆腔复发风险,外照射采用调强放疗联合每日图像引导放疗;推荐对FIGO I-II期高危组织学类型及FIGO III-IVA期任何组织学类型患者行化疗;前哨淋巴结示踪推荐用于手术淋巴结分期。

要点

  • 推荐根据临床病理风险因素给予辅助放疗(阴道近距离放疗或外照射)以降低阴道和/或盆腔复发风险。
  • 外照射放疗时推荐调强放疗联合每日图像引导放疗以减少急性和晚期毒性。
  • 推荐对FIGO I-II期高危组织学类型及FIGO III-IVA期任何组织学类型患者行化疗。

核心结论

  • 这些推荐为子宫内膜癌辅助治疗的使用提供了循证最佳临床实践指导。

研究设计与样本

  • 美国放射肿瘤学会召集多学科工作组,基于系统文献综述和预设共识构建方法及证据质量分级与推荐强度系统制定推荐,聚焦子宫内膜癌辅助管理的6个关键问题。

主要发现

  • 工作组推荐根据患者临床病理风险因素给予放疗(阴道近距离放疗或外照射放疗)以降低阴道和/或盆腔复发风险。
  • 当给予外照射放疗时,推荐调强放疗联合每日图像引导放疗以减少急性和晚期毒性。
  • 推荐对FIGO I-II期高危组织学类型患者及FIGO III-IVA期任何组织学类型患者行化疗。
  • 在化疗与放疗序贯安排方面,没有前瞻性数据支持最佳顺序。
  • 推荐前哨淋巴结示踪而非盆腔淋巴结清扫用于手术淋巴结分期;前哨淋巴结病理超分期数据支持孤立的肿瘤细胞患者按淋巴结阴性处理,微转移患者按淋巴结阳性处理。

关键数值与推荐

  • 推荐根据临床病理风险因素给予放疗(阴道近距离放疗或外照射放疗)以降低阴道和/或盆腔复发风险。
  • 当给予外照射放疗时,推荐调强放疗联合每日图像引导放疗以减少急性和晚期毒性。
  • 推荐对FIGO I-II期高危组织学类型患者及FIGO III-IVA期任何组织学类型患者行化疗。
  • 推荐前哨淋巴结示踪而非盆腔淋巴结清扫用于手术淋巴结分期。
  • 前哨淋巴结病理超分期数据支持孤立的肿瘤细胞患者按淋巴结阴性处理,微转移患者按淋巴结阳性处理。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 在化疗与放疗序贯安排方面,没有前瞻性数据支持最佳顺序。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: With the results of several recently published clinical trials, this guideline informs on the use of adjuvant radiation therapy (RT) and systemic therapy in the treatment of endometrial cancer. Updated evidence-based recommendations provide indications for adjuvant RT and the associated techniques, the utilization and sequencing of adjuvant systemic therapies, and the effect of surgical staging techniques and molecular tumor profiling. METHODS: The American Society for Radiation Oncology convened a multidisciplinary task force to address 6 key questions that focused on the adjuvant management of patients with endometrial cancer. The key questions emphasized the (1) indications for adjuvant RT, (2) RT techniques, target volumes, dose fractionation, and treatment planning aims, (3) indications for systemic therapy, (4) sequencing of systemic therapy with RT, (5) effect of lymph node assessment on utilization of adjuvant therapy, and (6) effect of molecular tumor profiling on utilization of adjuvant therapy. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and system for quality of evidence grading and strength of recommendation. RESULTS: The task force recommends RT (either vaginal brachytherapy or external beam RT) be given based on the patient's clinical-pathologic risk factors to reduce risk of vaginal and/or pelvic recurrence. When external beam RT is delivered, intensity modulated RT with daily image guided RT is recommended to reduce acute and late toxicity. Chemotherapy is recommended for patients with International Federation of Gynecology and Obstetrics (FIGO) stage I to II with high-risk histologies and those with FIGO stage III to IVA with any histology. When sequencing chemotherapy and RT, there is no prospective data to support an optimal sequence. Sentinel lymph node mapping is recommended over pelvic lymphadenectomy for surgical nodal staging. Data on sentinel lymph node pathologic ultrastaging status supports that patients with isolated tumor cells be treated as node negative and adjuvant therapy based on uterine risk factors and patients with micrometastases be treated as node positive. The available data on molecular characterization of endometrial cancer are compelling and should be increasingly considered when making recommendations for adjuvant therapy. CONCLUSIONS: These recommendations guide evidence-based best clinical practices on the use of adjuvant therapy for endometrial cancer.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Harkenrider MM, Abu-Rustum N, Albuquerque K, et al. Radiation Therapy for Endometrial Cancer: An American Society for Radiation Oncology Clinical Practice Guideline. Pract Radiat Oncol. 2022. PMID: 36280107. doi:10.1016/j.prro.2022.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。